Immunology
Commentary
The steep costs of disrupting gut-barrier harmony
When the gut barrier is disrupted by factors such as infection, low-fiber diet, antibiotics, and alcohol, then it cannot function normally to...
Latest News
Review finds no CV or VTE risk signal with use of JAK inhibitors for skin indications
Of the 35 trials studied, most involved patients with atopic dermatitis.
News from the FDA/CDC
New meningococcal vaccine wins FDA approval
The vaccine “has the potential to protect more adolescents and young adults from this severe and unpredictable disease by providing the broadest...
Conference Coverage
Asthma with EoE linked to earlier hospitalization
Double atopic disease could be causing more inflammation, but more research is needed.
Conference Coverage
Asthma severity higher among LGBTQ+ population
SGM respondents were significantly more likely to have had asthma attacks requiring steroid use in the past years.
Conference Coverage
New RSV vaccine will cut hospitalizations, study shows
With widespread use of the vaccine, annual hospitalizations resulting from infant RSV would fall by 51%, emergency department encounters would...
News
Guillain-Barré syndrome: Honing treatment strategies
Classic subtypes of Guillain-Barré syndrome are varying manifestations of a shared disease process, novel insights into the disease indicate. This...
Commentary
Atopic dermatitis: Five things to know
The incidence of AD has increased over the past several decades, and environmental factors such as climate change have been implicated as a...
Article
52-year-old man • intermittent fevers • recently received second dose of COVID-19 vaccine • tremors in all 4 extremities • Dx?
► Intermittent fevers
► Recently received second dose of COVID-19 vaccine
► Tremors in all 4 extremities
From the Journals
Maternal pertussis vax effective for infants in most vulnerable months
Large study also helps answer questions on duration of effectiveness and the potential “blunting” effect in infants.
News from the FDA/CDC
FDA approves first tocilizumab biosimilar
Tocilizumab-bavi (Tofidence) will offer a lower-cost option for patients with autoimmune conditions, the drug manufacturer, Biogen, stated.